Surprised that dementia drug was rejected

Share this article with friends

EmailEmail Copy LinkCOPY

DEMENTIA Australia expressed disappointment over the Therapeutic Goods Administration’s (TGA) rejection of Lecanemab, a treatment for early-stage Alzheimer’s disease. Developed by Eisai, Lecanemab removes amyloid plaques to slow cognitive decline. Already approved in countries like the U.S. and UK, it was also recently rejected by the European Medicines Agency. CEO Tanya Buchanan emphasised that while not a cure, the drug offers hope and could improve quality of life for some Australians with early Alzheimer’s.

Article Details

Published in

Editors Picks